Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 643.05 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-26
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 6.66K shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-06-30 was 627.41K shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-03-31 was 8.98K shares, a 618.80% increase year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 643.05K shares, a 51344.32% increase from fiscal 2024.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 1.25K shares, a 88.53% decline from fiscal 2023.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 10.90K shares, a 85.98% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 77.75K shares, a 47.76% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 6.66K shares derived: sum of 2 quarters · filed 2026-03-26 | 634.07K shares derived: sum of 3 quarters · filed 2026-03-26 | 643.05K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 6.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 634.07K shares derived: sum of 2 quarters · filed 2025-11-06 | 643.05K shares 10-Q · filed 2025-11-06 | 643.05K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 627.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 636.39K shares 10-Q · filed 2025-08-07 | 636.39K shares derived: sum of 3 quarters · filed 2025-08-07 | 636.39K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 8.98K shares 10-Q · filed 2025-05-07 | 8.98K shares derived: sum of 2 quarters · filed 2025-05-07 | 8.98K shares derived: sum of 3 quarters · filed 2025-05-07 | 8.98K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-20 | 0.00 shares derived: sum of 3 quarters · filed 2025-03-20 | 1.25K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-13 | 1.25K shares 10-Q · filed 2024-11-13 | 1.25K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.25K shares 10-Q · filed 2024-08-08 | 1.25K shares derived: sum of 3 quarters · filed 2024-08-08 | 5.33K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.25K shares 10-Q · filed 2024-05-07 | 1.25K shares derived: sum of 2 quarters · filed 2024-05-07 | 5.33K shares derived: sum of 3 quarters · filed 2024-05-07 | 9.97K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 4.08K shares derived: sum of 2 quarters · filed 2024-03-26 | 8.72K shares derived: sum of 3 quarters · filed 2024-03-26 | 10.90K shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 4.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 8.72K shares derived: sum of 2 quarters · filed 2023-11-02 | 10.90K shares 10-Q · filed 2023-11-02 | 88.19K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 4.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 6.82K shares 10-Q · filed 2023-08-08 | 84.11K shares derived: sum of 3 quarters · filed 2023-08-08 | 42.83K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 2.18K shares 10-Q · filed 2023-05-04 | 79.47K shares derived: sum of 2 quarters · filed 2023-05-04 | 38.20K shares derived: sum of 3 quarters · filed 2023-05-04 | |
| 2022-12-31 | 77.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 36.02K shares derived: sum of 2 quarters · filed 2023-03-23 | 77.75K shares 10-K · filed 2023-03-23 | |
| 2022-09-30 | -41.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 463.00 shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 41.74K shares 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 148.84K shares 10-K · filed 2022-03-30 | ||
| 2021-09-30 | 148.84K shares 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |